Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ALOX5 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for ALOX5, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ALOX15 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for ALOX15, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ALOX12B 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for ALOX12B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ALOX12 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for ALOX12, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ALDH2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for ALDH2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
AIM2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for AIM2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
AIFM2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for AIFM2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ADRB3 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for ADRB3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ADRB2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for ADRB2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ADRB1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for ADRB1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ADRA2B 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for ADRA2B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
ADRA2A 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for ADRA2A, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.